News Search Results
Jan 08, 2025, 07:42 ET NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025
2024, is an important step in facilitating the previously announced proposed merger with Kadimastem, which aims to create a combined Nasdaq-traded biotechnology company with product candidates in advanced stages of clinical development. Additionally, as previously announced, NLS recently filed an
More news about: Kadimastem Ltd.; NLS Pharmaceutics Ltd.
Jan 08, 2025, 07:33 ET Abzena Strengthens Board with Appointment of Biopharma Industry Leader, Dr Moncef Slaoui
Board of Directors of several companies including Cedar Health, Arcturus Therapeutics, Altesa, Zephyr AI and Vicebio. He has previously sat on biotechnology company boards for Moderna, Inc., Lonza Group AG, Galvani, and Vaxcyte. During the COVID-19 pandemic, he served as the Chief Scientific Advisor
More news about: Abzena
Jan 08, 2025, 07:11 ET Latest Updates of Viva Biotech's Portfolio Companies
January 3, 2025, VivaVision Biotech ("VivaVision"), invested and incubated by VBI, a clinical-stage, privately held biotechnology company focused on developing treatments for ocular diseases, announced that VVN461 achieves clinical endpoints in Phase II clinical trial for non-infectious
More news about: Viva Biotech
Jan 08, 2025, 07:11 ET 維亞生物投資孵化公司近期發展動態一覽
Circles Therapeutics （簡稱爲「Full Circles」）在頂級期刊《Nature Biotechnology》上發表了一項突破性研究「Efficient non-viral immune cell engineering using circular single-stranded DNA-mediated genomic integration」。該研究介紹了一種非病毒的新型環狀單鏈DNA技術（cssDNA），可在多種細胞類型中實現高效的大片段基因接入，可携帶基因序列最長可達20Kb。
More news about: Viva Biotech
Jan 08, 2025, 07:00 ET 1cBio and Alesta Therapeutics Announce Exclusive Global Licensing Agreement for a Novel Potentially First-in-Class Small Molecule for Hypophosphatasia
royalties on global sales, contingent upon successful development and commercialization. About 1cBio1cBio is an emerging biotechnology company which strives to identify white spaces in cancer therapies and develop molecules that can serve as precision medicines. The company's programs
More news about: 1cBio
Jan 08, 2025, 07:00 ET Alesta Therapeutics Raises €65 Million Series A Financing to Advance Oral Small Molecules for Rare Diseases
Netherlands, Jan. 8, 2025 /PRNewswire/ -- Alesta Therapeutics, a biotechnology company focused on developing transformative small molecule therapies for rare diseases, today announced the closing of an oversubscribed €65 million
More news about: Alesta Therapeutics
Jan 08, 2025, 07:00 ET Marengo's First-in-Class Invikafusp Alfa (STAR0602) Receives U.S. FDA Fast Track Designation for Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancers with High Tumor Mutational Burden (TMB-H)
Mass., Jan. 8, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision T cell activation, today announced that the U.S. Food and Drug Administration (FDA) has granted
More news about: Marengo Therapeutics
Jan 08, 2025, 07:00 ET Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Jan 08, 2025, 00:01 ET Dr. Eyal S. Ron Joins AmacaThera Board of Directors to Drive Strategic Growth and Accelerate Innovation in Long-Acting Therapies
TORONTO, Jan. 8, 2025 /PRNewswire/ - AmacaThera, a leading clinical-stage biotechnology company revolutionizing long-acting therapies, announces the appointment of Dr. Eyal S. Ron to its Board of Directors.
More news about: AmacaThera Inc.
Jan 08, 2025, 00:01 ET Dr. Eyal S. Ron Joins AmacaThera Board of Directors to Drive Strategic Growth and Accelerate Innovation in Long-Acting Therapies
TORONTO, Jan. 8, 2025 /PRNewswire/ -- AmacaThera, a leading clinical-stage biotechnology company revolutionizing long-acting therapies, announces the appointment of Dr. Eyal S. Ron to its Board of Directors.
More news about: AmacaThera Inc.
Jan 07, 2025, 22:30 ET GenScript Biotech Becomes a PSCI Supplier Partner, Advancing a Sustainable Pharmaceutical Supply Chain
tools, are widely recognized and respected across the global pharmaceutical sector. "As a responsible global enterprise in life sciences and biotechnology, GenScript is honored to become a PSCI Supplier Partner," said Sherry Shao, rotating CEO of GenScript Biotech Corporation.
More news about: GenScript Biotech Corporation
Jan 07, 2025, 20:56 ET Promise Exchange Program Debuts at CES in Las Vegas Showcasing 7 Tunisian Startups
multidimensional approach: predicting risks, detecting them in time and assisting response teams. SPIRAW | Food Tech SPIRAW combines biotechnology and IoT to offer a home-based solution for growing fresh, high-quality spirulina. Inspired by Nespresso, our innovative machine automates cultivation,
More news about: Tunisian American Young Professionals (TAYP)
Jan 07, 2025, 17:02 ET Stockholder Notice: Robbins LLP Informs Stockholders of the Revance Therapeutics, Inc. Class Action Lawsuit
(NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024. Revance is a biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the U.S. and internationally.
More news about: Robbins LLP
Jan 07, 2025, 12:55 ET Global Market for Cell and Gene Therapy Tools and Reagents Projected to Grow at a 10.8% CAGR
projects growth through 2029, analyzing applications such as drug development, agriculture, and diagnostics. It also examines end users, including biotechnology and pharmaceutical companies, academic and government research institutes, and contract research organizations. Directly purchase
More news about: BCC Research LLC
Jan 07, 2025, 12:43 ET Virbac Introduces URSOLYX™ Soft Chews: Innovation in Canine Muscle Health
Emmyon, Inc., a biotechnology company specializing in skeletal muscle biology, to introduce URSOLYX™ Soft Chews. This first-in-its-class muscle support product features ursolic
More news about: Virbac
Jan 07, 2025, 12:07 ET Rubin and Rudman Partner Ted Folkman Named a 2024 "Go To Business Litigation Lawyer" by Massachusetts Lawyers Weekly
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Jan 07, 2025, 12:00 ET MedicosBiotech Wins CES 2025 Innovation Award in Digital Health
possible, unlocking the full potential of this remarkable material. "This award recognizes MedicosBiotech's innovative fusion of AI and biotechnology," said Soon Cheol Daniel Kim, COO of MedicosBiotech. "Cure Silk is an affordable, easy-to-use solution that enhances
More news about: MedicosBiotech
Jan 07, 2025, 11:11 ET Cellulase Market Analysis 2024-2030: Insights into Biofuels, Animal Feed, and Textile Applications | Valuates Reports
China, India, and Japan, as well as increasing investments in biotechnology research and development. Latin America and the Middle East also show promising
More news about: Valuates Reports
Jan 07, 2025, 11:00 ET PostEra announces expansion to $610M in their AI drug discovery collaboration with Pfizer
PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an expansion of their partnership with Pfizer. The parties
More news about: PostEra
Jan 07, 2025, 11:00 ET PostEra announces expansion to $610M in their AI drug discovery collaboration with Pfizer
PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an expansion of their partnership with Pfizer. The parties
More news about: PostEra
Jan 07, 2025, 10:00 ET FitBiomics Announces Monumental Advancement in Biome Research Poised to Transform Sleep and Gut Health Interventions Worldwide
FitBiomics, a leading biotechnology company using microbiome innovation to create next-generation probiotics, announced today the release of its latest research on the sleep-exercise-microbiome
More news about: FitBiomics
Jan 07, 2025, 10:00 ET Lilly to participate in J.P. Morgan Healthcare Conference
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jan 07, 2025, 09:07 ET Pholoho Biotechnology Announces Success in Extracting and Purifying the Biomolecule C-Phycocyanin for Cancer Research and Treatment
NB, Jan. 7, 2025 /PRNewswire/ - Pholoho Biotechnology, an innovative company in the field of biotechnology, is proud to announce a significant achievement with the extraction and purification of C-Phycocyanin, a biomolecule derived
More news about: Pholoho Biotechnology
Jan 07, 2025, 09:00 ET Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease
ISM5411 were recently published in Nature Biotechnology, which represents the new PCC nomination record published in a peer-reviewed journal, beating Insilico's previous record of 18 months also
More news about: Insilico Medicine
Jan 07, 2025, 09:00 ET Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
2025 /PRNewswire/ -- Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, and Duality Biotherapeutics ("DualityBio"), a clinical-stage biotech company focusing on
More news about: Duality Biotherapeutics